Circulating tumor cells to predict survival and monitor treatment response in patients with advanced HCC
Recruiting
- Conditions
- C22.0Liver cell carcinoma
- Registration Number
- DRKS00029565
- Lead Sponsor
- Klinikum der Universität München, Campus Großhadern
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
1. Male and female patients.
2. Age =18 years.
3. Patients with a histological/cytological or radiological diagnosis of HCC.
4. Patient informed consent.
Exclusion Criteria
1. Inability to provide written informed consent.
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Prognostic value of baseline total CTC and baseline PD-L1-positive (PD-L1+) CTC
- Secondary Outcome Measures
Name Time Method - Correlation of quantitative changes in CTC count and PD-L1+ CTC count with radiological response.<br>- Correlation of total CTC and PD-L1+ CTC over the course of therapy with survival<br>- Correlation of imaging and AFP with clinical endpoints (survival, response) and comparison of performance of imaging and AFP with CTC and PD-L1+ CTC